Industrie
Showing 281–290 Di 310 risultati
-
Bladder Cancer Market in China
Secondo StrategyHelix, the bladder cancer market in China, in terms of volume, is expected to expand at a CAGR of 3.1% nel periodo di analisi di 2021 A 2027.
-
Pancreatic Cancer Market in China
According to a statistic by StrategyHelix, the pancreatic cancer market in China, in terms of volume, is expected to expand at a CAGR of 3.3% durante il periodo di previsione (2021-2027).
-
Lymphoma Market in China
Secondo StrategyHelix, the lymphoma market in China, in terms of volume, is expected to expand at a CAGR of 2.3% in the next five years.
-
Urothelial Cancer Market in China
According to a statistic by StrategyHelix, the urothelial cancer market in China, in terms of volume, is expected to expand at a CAGR of 3.2% da 2021 Attraverso 2027.
-
Gastric Cancer Market in China
The gastric cancer market in China was estimated at 470 thousand units in 2020 and is anticipated to reach 579 thousand units by 2027, procedendo a un CAGR di 3% throughout the forecast period, secondo StrategyHelix.
-
Breast Cancer Market in China
Secondo StrategyHelix, the breast cancer market in China, in terms of volume, is expected to expand at a CAGR of 1.2% da 2021 Attraverso 2027.
-
Non-small-cell Lung Carcinoma (NSCLC) Mercato in Cina
At 3% CAGR, the non-small-cell lung carcinoma (NSCLC) market in China is projected to reach 967 thousand units by 2027, secondo la società di dati e analisi StrategyHelix.
-
Nasopharyngeal Cancer Market in China
According to a statistic by StrategyHelix, the nasopharyngeal cancer market in China, in terms of volume, is expected to expand at a CAGR of 1.2% in the next five years.
-
Head and Neck Cancer Market in China
The head and neck cancer market in China, in terms of volume, is expected to expand at a CAGR of 1.7% da 2021 Attraverso 2027, secondo la società di dati e analisi StrategyHelix.
-
Oncology Drug Market in China
The oncology drug market in China is poised to grow at a CAGR of around 13.3% nel periodo di analisi di 2021 A 2027, secondo la società di dati e analisi StrategyHelix.